Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / HEXIM1

HEXIM1

Basics

Aliases:
This biomarker is also known as:
  • Estrogen down-regulated gene 1 protein,
  • Hexamethylene bis-acetamide-inducible protein 1,
  • CLP1,
  • estrogen down-regulated gene 1 protein,
  • hexamethylene bis-acetamide inducible 1,
  • Cardiac lineage protein 1,
  • menage a quatre protein 1,
  • EDG1,
  • protein HEXIM1,
  • hexamethylene bis-acetamide-inducible protein 1,
  • hexamethylene-bis-acetamide-inducible transcript 1,
  • HMBA-inducible,
  • Menage a quatre protein 1,
  • CLP-1,
  • hexamthylene bis-acetamide inducible 1,
  • HIS1,
  • MAQ1,
  • menage a quatre 1,
  • cardiac lineage protein 1,
  • hexamethylene bisacetamide-inducible protein,

View in BioMuta

Description…

HEXIM1 is an intronless transcriptional regulator which functions as a general RNA polymerase II transcription inhibitor. HEXIM1 expression is induced by hexamethylene-bis-acetamide in vascular smooth muscle cells.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

HEXIM1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html